210 related articles for article (PubMed ID: 31494105)
1. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
[TBL] [Abstract][Full Text] [Related]
2. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
[TBL] [Abstract][Full Text] [Related]
3. Berberine and palmatine inhibit the growth of human rhabdomyosarcoma cells.
Shinji S; Nakamura S; Nihashi Y; Umezawa K; Takaya T
Biosci Biotechnol Biochem; 2020 Jan; 84(1):63-75. PubMed ID: 31462179
[TBL] [Abstract][Full Text] [Related]
4. Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
Wei C; Li X
BMC Cancer; 2020 Oct; 20(1):1042. PubMed ID: 33121449
[TBL] [Abstract][Full Text] [Related]
5. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
[TBL] [Abstract][Full Text] [Related]
6. Verteporfin inhibits growth of human glioma in vitro without light activation.
Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
[TBL] [Abstract][Full Text] [Related]
7. Verteporfin induces apoptosis and reduces the stem cell-like properties in Neuroblastoma tumour-initiating cells through inhibition of the YAP/TAZ pathway.
Fusco P; Mattiuzzo E; Frasson C; Viola G; Cimetta E; Esposito MR; Tonini GP
Eur J Pharmacol; 2021 Feb; 893():173829. PubMed ID: 33347823
[TBL] [Abstract][Full Text] [Related]
8. Novel Roles for Staufen1 in Embryonal and Alveolar Rhabdomyosarcoma via c-myc-dependent and -independent events.
Crawford Parks TE; Marcellus KA; Langill J; Ravel-Chapuis A; Michaud J; Cowan KN; Côté J; Jasmin BJ
Sci Rep; 2017 Feb; 7():42342. PubMed ID: 28211476
[TBL] [Abstract][Full Text] [Related]
9. Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells.
Wei C; Li X
Mol Med Rep; 2020 Nov; 22(5):3955-3961. PubMed ID: 32901856
[TBL] [Abstract][Full Text] [Related]
10. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
[TBL] [Abstract][Full Text] [Related]
11. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
[TBL] [Abstract][Full Text] [Related]
12. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
[TBL] [Abstract][Full Text] [Related]
13. Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein Survivin in a light-independent manner.
Hasegawa T; Sugihara T; Hoshino Y; Tarumoto R; Matsuki Y; Kanda T; Takata T; Nagahara T; Matono T; Isomoto H
Oncol Lett; 2021 Oct; 22(4):703. PubMed ID: 34457058
[TBL] [Abstract][Full Text] [Related]
14. Verteporfin Inhibits the Progression of Spontaneous Osteosarcoma Caused by Trp53 and Rb1 Deficiency in Ctsk-Expressing Cells via Impeding Hippo Pathway.
Li Y; Yang S; Yang S
Cells; 2022 Apr; 11(8):. PubMed ID: 35456040
[TBL] [Abstract][Full Text] [Related]
15. Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma.
Slemmons KK; Crose LE; Rudzinski E; Bentley RC; Linardic CM
PLoS One; 2015; 10(10):e0140781. PubMed ID: 26496700
[TBL] [Abstract][Full Text] [Related]
16. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
[TBL] [Abstract][Full Text] [Related]
17. The Hippo pathway mediates inhibition of vascular smooth muscle cell proliferation by cAMP.
Kimura TE; Duggirala A; Smith MC; White S; Sala-Newby GB; Newby AC; Bond M
J Mol Cell Cardiol; 2016 Jan; 90():1-10. PubMed ID: 26625714
[TBL] [Abstract][Full Text] [Related]
18. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
Barrette AM; Ronk H; Joshi T; Mussa Z; Mehrotra M; Bouras A; Nudelman G; Jesu Raj JG; Bozec D; Lam W; Houldsworth J; Yong R; Zaslavsky E; Hadjipanayis CG; Birtwistle MR; Tsankova NM
Neuro Oncol; 2022 May; 24(5):694-707. PubMed ID: 34657158
[TBL] [Abstract][Full Text] [Related]
19. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
20. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]